| Description |
UNC-926 is a methyl-lysine (Kme) reader domain inhibitor; inhibits L3MBTL1 with an IC50 of 3.9 μM.
|
| Related Catalog |
|
| Target |
IC50: 3.9 μM (L3MBTL1)[1]
|
| In Vitro |
UNC-926 inhibits L3MBTL1 with an IC50 of 3.9 μM. L3MBTL1UNC-926 also exhibits a low micromolar affinity for the close homolog, L3MBTL3, with a decrease in affinity for the other MBT domains and no binding to CBX7. UNC-926 inhibits binding of the 3xMBT domain to H4K20me1. It selectively inhibits the L3MBTL13xMBT-H4K20me1 interaction in a dose-dependent manner. UNC-926 does not have an effect on the binding of 53BP1 to H4K20me1, demonstrating specificity of UNC-926 for L3MBTL1 over 53BP1[1].
|
| References |
[1]. Herold JM, et al. Structure–activity relationships of methyl-lysine reader antagonists. MedChemComm. 2012;3(45):45–51.
|
